Hypertension and Dyslipidemia Management

Pathophysiology and Risk Assessment

The American Heart Association suggests that hypertension accelerates atherosclerosis primarily through mechanical and hemodynamic forces, including elevated systolic blood pressure, which increases left ventricular output impedance and intramyocardial wall tension, raising myocardial oxygen demand while simultaneously reducing coronary flow reserve 1
The European Society of Cardiology indicates that elevated LDL-cholesterol demonstrates a strong, independent, graded relationship with coronary heart disease risk that fulfills causality criteria 2
The atherogenic lipid triad (elevated triglycerides, small dense LDL particles, and low HDL-cholesterol) creates particularly aggressive atherosclerotic disease, according to the European Heart Journal 3

The American College of Cardiology recommends that blood pressure treatment threshold drops to 130/80 mmHg in patients with additional cardiovascular risk factors including dyslipidemia 1
The European Society of Cardiology classifies severe hypertension combined with familial dyslipidemia as "high risk" (5-10% 10-year cardiovascular mortality) even without other risk factors 4, 5, 6
The European Society of Cardiology suggests that very high risk patients (documented CVD, diabetes with target organ damage, or 10-year SCORE ≥10%) should initiate statin therapy immediately regardless of baseline LDL-cholesterol 4, 5

The American Heart Association warns that treating hypertension or dyslipidemia in isolation without assessing total cardiovascular risk leads to undertreatment of high-risk patients 1, 4
The American College of Cardiology advises against failing to screen for secondary causes (hypothyroidism, kidney disease, alcohol abuse, medications) before initiating therapy, as it misses reversible etiologies 2